RAYMED LABS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.39 INR | +4.82% |
|
+4.82% | -2.85% |
| May. 24 | Raymed Labs Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| May. 24 | Raymed Labs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 9.487 | 9.786 | 4.145 | 4.103 | 6.752 | 8.718 |
| Enterprise Value (EV) 1 | 29.86 | 30.25 | 24.83 | 26.22 | 7.245 | 9.212 |
| P/E ratio | -17.1 x | -18.3 x | -7.46 x | -5.96 x | -8.23 x | -5.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -141 x | -171 x | -144 x | -41.5 x | -9.42 x | -5.57 x |
| EV / FCF | 97.6 x | 104 x | 125 x | -22.3 x | -50.3 x | -9.24 x |
| FCF Yield | 1.02% | 0.96% | 0.8% | -4.49% | -1.99% | -10.8% |
| Price to Book | -0.51 x | -0.51 x | -0.21 x | -0.2 x | -0.32 x | -0.38 x |
| Nbr of stocks (in thousands) | 4,274 | 4,274 | 4,274 | 4,274 | 4,274 | 4,274 |
| Reference price 2 | 2.220 | 2.290 | 0.9700 | 0.9600 | 1.580 | 2.040 |
| Announcement Date | 9/29/18 | 9/4/19 | 11/25/20 | 8/29/21 | 8/30/22 | 8/7/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -0.2115 | -0.1766 | -0.1723 | -0.6315 | -0.7688 | -1.655 |
| EBIT 1 | -0.2789 | -0.2403 | -0.2324 | -0.6883 | -0.8206 | -1.709 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.5664 | -0.5354 | -0.5569 | -0.6883 | -0.8206 | -1.709 |
| Net income 1 | -0.5664 | -0.5354 | -0.5569 | -0.6883 | -0.8206 | -1.709 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.1300 | -0.1250 | -0.1300 | -0.1611 | -0.1920 | -0.4000 |
| Free Cash Flow 1 | 0.3059 | 0.2916 | 0.1984 | -1.177 | -0.144 | -0.9968 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/29/18 | 9/4/19 | 11/25/20 | 8/29/21 | 8/30/22 | 8/7/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 20.4 | 20.5 | 20.7 | 22.1 | 0.49 | 0.49 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -96.34 x | -115.9 x | -120 x | -35.02 x | -0.6412 x | -0.2988 x |
| Free Cash Flow 1 | 0.31 | 0.29 | 0.2 | -1.18 | -0.14 | -1 |
| ROE (net income / shareholders' equity) | 3.07% | 2.82% | 2.85% | 3.41% | 3.92% | 7.7% |
| ROA (Net income/ Total Assets) | -6.37% | -5.61% | -5.57% | -16.9% | -20.6% | -53.2% |
| Assets 1 | 8.886 | 9.537 | 10.01 | 4.069 | 3.983 | 3.215 |
| Book Value Per Share 2 | -4.390 | -4.510 | -4.640 | -4.800 | -5.000 | -5.400 |
| Cash Flow per Share 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 9/29/18 | 9/4/19 | 11/25/20 | 8/29/21 | 8/30/22 | 8/7/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- RAYLA Stock
- Financials Raymed Labs Limited
